Laura Marie Hartmann

Laura Marie Hartmann

Auto-generated profile, based on publicly available information

Laura Marie Hartmann


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in bioRxiv
Verified
Preprint
Open access
IKIsabell Kassing
Isabell Kassing
JKJonas Kath
Jonas Kath
ANAna-Maria Nitulescu
Ana-Maria Nitulescu
VGViktor Glaser
Viktor Glaser
LHLaura M. Hartmann
Laura M. Hartmann
DWDimitrios L. Wagner
Dimitrios L. Wagner
Current gene transfer methods often lack the precision, versatility, or efficiency when integrating large transgenes, limiting the ability to engineer therapeutic T-cells with more complex payloads. Here, we report ‘one-pot’ PASTA (Programmable and Site-specific Transgene Addition), a non-viral genome engineering strategy for large gene insertion that combines CRISPR-Cas-mediated homology-directed repair (HDR) and site-specific recombination via serine integrases. Using ‘one-pot’ PASTA with the Bxb1 integrase, we demonstrate efficient integration of transgenes at multiple genomic loci relevant for T-cell engineering (e.g., TRAC, B2M, CD3E, CD3Z, GAPDH ). For constructs > 8 kb, ‘one-pot’ PASTA outperforms conventional HDR by 19-fold on average and prime-editing-assisted site-specific integrase gene editing (PASSIGE) by 5-fold. This enables the delivery of multi-cistronic cargo to generate dual-antigen targeting CAR T-cells with a safety-switch that overcome antigen escape in lymphoma models. Finally, ‘one-pot’ PASTA can be further optimized with improved integrase enzymes, such as engineered variants of Pa01 or Bxb1, and plasmids with minimized backbones. In summary, ‘one-pot’ PASTA represents a versatile and scalable platform for precise, non-viral gene insertion in T-cells.

15 September 2025 in bioRxiv
Verified
Preprint
Open access
VGViktor Glaser
Viktor Glaser
LBLily Jo Becker
Lily Jo Becker
CFCarla Fuster
Carla Fuster
LHLuis Huth
Luis Huth
ANAna-Maria Nitulescu
Ana-Maria Nitulescu
DWDimitrios Laurin Wagner
Dimitrios Laurin Wagner
The CRISPR-Cas system enables precise genome engineering of cell therapies. For allogeneic applications, multiplex editing is frequently required to improve efficacy, persistence, and safety. However, strategies involving multiple DNA double-strand breaks (DSBs) induce genotoxicity by provoking chromosomal aberrations. Base editors, which enable sequence changes without generating DSBs, are widely used for gene disruption, but their capacity for gene insertion remains unexplored. Here, we developed B ase e ditor-mediated k nock- i n ( BEKI ), a non-viral platform that allows targeted transgene insertion in parallel with multiplex gene disruption using a single base editor. Repurposing the Cas9 nickase domain of base editors generates paired nicks, inducing homology-directed repair (HDR). In human T cells, optimized guide RNA orientation and nick distance, together with HDR-enhancing modulators, enabled efficient transgene knock-in at the TRAC , CD3ζ, B2M, and CD3ε loci. Simultaneous base editing of multiple additional genes produced chimeric antigen receptor (CAR) T cells with increased cytokine secretion, drug resistance, and resistance to allo-rejection. Compared to multiplex editing with Cas9, BEKI markedly reduced chromosomal translocations. BEKI therefore provides a streamlined, scalable strategy for multiplex CAR T-cell engineering with a single enzyme, offering a safer route to clinical-grade manufacturing of off-the-shelf therapies for cancer and autoimmune diseases. Graphical